By a News Reporter-Staff News Editor at Drug Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting from Vienna, Austria, by NewsRx journalists, research stated, "The currently applied immunotherapy of type I allergy with aluminum hydroxide (alum) as adjuvant elicits - among other side effects - an initial IgE-boost. In contrast, CpG-oligodeoxynucleotides (ODNs) drive the immune response toward Th1."
The news correspondents obtained a quote from the research from Medical University, "The biodegradable material protamine can spontaneously form nanoparticles together with such ODNs. Our aim was to investigate the immune response induced by protamine-based. nanoparticles (proticles) with CpG-ODN as an allergen delivery system. Proticles complexed with Ara h 2 extracted from raw peanuts as model allergen were injected subcutaneously into naive BALB/c mice. Ara h 2-specific antibodies were analyzed by ELISA and rat basophilic leukemia (RBL) cell assay. Cytokine levels were investigated in supernatants of stimulated splenocytes. The in vivo distribution after subcutaneous injection was examined via fluorescence imaging. BMDCs were stimulated with proticles, and expression of stimulation and maturation markers as well as cytokines in supernatants was investigated. A favorable increase in Ara h 2-specific IgG2a antibodies was found after immunization with proticlesAra h 2, whereas Ara h 2-specific IgE was not detectable. Accordingly, the ratio of IL-5/IFN-gamma was low in this group. Granuloma formation was completely absent at injection sites of proticles. The distribution of Ara h 2 after subcutaneous injection was markedly decelerated when complexed to proticles. Stimulation of BMDCs with proticles-Ara h 2 caused upregulation of CD11c and CD80 as well as an increased IL-6 production."
According to the news reporters, the research concluded: "Our data suggest that biodegradable protamine-based nanoparticles with CpG-ODN counteract the Th2-dominated immune response induced by an allergen and therefore are suitable as novel carrier system for immunotherapy of allergy."
For more information on this research see: Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. European Journal of Pharmaceutics and Biopharmaceutics, 2013;85(3):656-664. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
Our news journalists report that additional information may be obtained by contacting I. Pali-Scholl, Medical University of Vienna, Dept. of Pediat & Adolescent Med, A-1090 Vienna, Austria. Additional authors for this research include H. Szollosi, P. Starkl, B. Scheicher, C. Stremnitzer, A. Hofmeister, F. Roth-Walter, A. Lukschal, S.C. Diesner, A. Zimmer and E. Jensen-Jarolim (see also Biotechnology).
Keywords for this news article include: Antibodies, Biotechnology, Vienna, Europe, Austria, Immunology, Protamines, Nanoparticle, Immunotherapy, Blood Proteins, Nanotechnology, Nucleoproteins, Immunoglobulins, Immunomodulation, Nuclear Proteins, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC